INT10873

From wiki-pain
Revision as of 12:40, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 21
Total Number 21
Disease Relevance 10.43
Pain Relevance 1.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Twist1) nucleus (Twist1) DNA binding (Twist1)
transcription factor binding (Twist1)
Anatomy Link Frequency
brain 2
myocardium 1
epithelium 1
Uterine 1
T-cells 1
Twist1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 207 98.48 Very High Very High Very High
cytokine 71 94.84 High High
long-term potentiation 106 88.96 High High
cva 33 88.64 High High
anesthesia 7 86.52 High High
Pain 9 85.32 High High
depression 19 69.28 Quite High
Arthritis 45 67.20 Quite High
Hippocampus 18 66.96 Quite High
ketamine 1 61.60 Quite High
Disease Link Frequency Relevance Heat
Cancer 149 100.00 Very High Very High Very High
Papilledema 4 100.00 Very High Very High Very High
Cervical Cancer 1 99.80 Very High Very High Very High
Frailty 7 99.54 Very High Very High Very High
Age-related Macular Degeneration 481 99.00 Very High Very High Very High
INFLAMMATION 222 98.48 Very High Very High Very High
Apoptosis 69 97.40 Very High Very High Very High
Lymphatic System Cancer 11 97.36 Very High Very High Very High
Malignant Neoplastic Disease 21 96.24 Very High Very High Very High
Hypoxia 3 95.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
B and NFAT are located in the twist1 promoter at positions ?
Localization (located) of twist1
1) Confidence 0.74 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0 Pain Relevance 0
Targeting of twist1-expressing Th cells, by means of either addressing twist1 or a gene regulated by it, seems more promising, because it is more specific for repeatedly restimulated Th1 memory cells involved in chronic inflammation.
Localization (Targeting) of twist1-expressing associated with inflammation
2) Confidence 0.74 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0.86 Pain Relevance 0.37
Genetic haploinsufficiency of both twist1 and twist2 results in fatal systemic inflammatory immunopathology in mice, which die before day 14 (4).
Localization (haploinsufficiency) of twist1 associated with inflammation
3) Confidence 0.74 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0.54 Pain Relevance 0.20
In mammals PDE4, PDE7 and PDE8 hydrolyze cAMP selectively, PDE5, PDE6, and PDE9 hydrolyse cGMP selectively and the remaining five PDEs (PDE1, 2, 3, 10, and 11) hydrolyze both cAMP and cGMP.
Localization (hydrolyse) of PDE
4) Confidence 0.73 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0 Pain Relevance 0
Each participant was sent a survey via an email containing the instrument, as well as instructions for rating each domain according to its relevance for PDT in CPGs.
Localization (relevance) of PDT
5) Confidence 0.64 Published 2010 Journal Health Res Policy Syst Section Body Doc Link PMC2846928 Disease Relevance 0 Pain Relevance 0
One of the reasons for the less favorable outcome in treating an occult lesion such as IPCV might be the collateral damage to adjacent structures, such as choriocapillaris hypoperfusion and retinal pigment epithelium atrophy, due to the effect of PDT.8 The associated damage results in retinal edema and release of angiogenic factors, with reduction of retinal function demonstrated by multifocal electroretinography.9
Localization (release) of PDT in epithelium associated with papilledema and frailty
6) Confidence 0.53 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2964964 Disease Relevance 0.75 Pain Relevance 0.03
Singlet oxygen may be released from Pa-PDT-mediated damaged mitochondria [13].
Localization (released) of Pa-PDT
7) Confidence 0.53 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2731730 Disease Relevance 0.63 Pain Relevance 0
Six

deaths were reported for PDT.

Localization (reported) of PDT
8) Confidence 0.48 Published 2000 Journal Crit Care Section Body Doc Link PMC29040 Disease Relevance 0.25 Pain Relevance 0.04
In order to describe the therapeutic value of ranibizumab for the treatment of neovascular AMD, the efficacy of other treatments currently used—PDT with verteporfin, pegaptanib sodium, and off-label bevacizumab—is presented for comparison.
Localization (presented) of PDT associated with age-related macular degeneration
9) Confidence 0.32 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 0.86 Pain Relevance 0
In our series, both treatments were given in the same day with the rationale of reducing the damage resulting from VEGF release after PDT.
Localization (release) of PDT
10) Confidence 0.28 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698683 Disease Relevance 0.27 Pain Relevance 0
So, nonthermal laser may be necessary to disrupt the anatomical component of CNV that do not respond to VEGF inhibition (Dhalla et al 2006), and anti-VEGF might be necessary to reduce the damage of the VEGF released by PDT.
Localization (released) of PDT associated with age-related macular degeneration
11) Confidence 0.26 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698683 Disease Relevance 0.57 Pain Relevance 0
T-cells over normal bystander cells was observed in vitro, which suggests that Pc 4-PDT can potentially be utilized as a target-specific anticancer therapy for malignancies such as CTCL.
Localization (utilized) of PDT in T-cells associated with lymphatic system cancer
12) Confidence 0.19 Published 2010 Journal Advances in Hematology Section Body Doc Link PMC3004392 Disease Relevance 1.02 Pain Relevance 0.03
Macroscopic assessment of tumor response post PDT
Localization (assessment) of PDT associated with cancer
13) Confidence 0.12 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2212622 Disease Relevance 0.55 Pain Relevance 0.03
Application of PDT for Uterine Cervical Cancer

We have been performing PDT using Excimer Dye Laser (EDL) or YAG-OPO laser, a type

Localization (Application) of PDT in Uterine associated with cervical cancer
14) Confidence 0.11 Published 1999 Journal Diagn Ther Endosc Section Title Doc Link PMC2362637 Disease Relevance 0.62 Pain Relevance 0.17
There is also release of VEGF following PDT which can cause transient visual disturbance secondary to hyperpermeability induced by it.20 This was demonstrated by multifocal electroretinography.21
Localization (release) of PDT
15) Confidence 0.09 Published 2007 Journal Indian Journal of Ophthalmology Section Body Doc Link PMC2635983 Disease Relevance 0.66 Pain Relevance 0.08
Ranibizumab plus PDT
Localization (Ranibizumab) of PDT
16) Confidence 0.08 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698673 Disease Relevance 0.13 Pain Relevance 0
First, it is important to know the exact localization of specific PDE enzymes in the normal brain (see also Table 1).
Localization (localization) of PDE in brain
17) Confidence 0.08 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.57 Pain Relevance 0.15
First, more localization studies are required to obtain more knowledge about the localization of the specific PDE isoforms in different brain areas.
Localization (localization) of PDE in brain
18) Confidence 0.06 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.48 Pain Relevance 0.17
PDT can be used for both diagnosis and treatment.
Localization (used) of PDT
19) Confidence 0.04 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1297510 Disease Relevance 0.80 Pain Relevance 0.08
PDT provides a noninvasive treatment approach to tumor cell killing through the activation of photosensitizing drugs and the release of singlet molecular oxygen (Jerjes et al 2007).
Localization (release) of PDT associated with cancer
20) Confidence 0.03 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761172 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox